阿那白滞素抑制IL-1β信号揭示实验性致关节炎甲病毒感染中骨丢失的关键作用
本研究在小鼠模型中评估临床类风湿关节炎药物阿那白滞素抑制IL-1β信号对罗斯河病毒(RRV)和基孔肯雅病毒(CHIKV)感染所致骨丢失的影响。结果显示阿那白滞素减轻RRV和CHIKV诱导的骨丢失,但未改善疾病评分、体重下降或病毒血症。提示IL-1β信号在致关节炎甲病毒感染的骨丢失中起关键作用,但其他临床特征不受影响。
要点
- 阿那白滞素减轻RRV和CHIKV感染小鼠的骨丢失。
- 阿那白滞素未改善疾病评分、体重下降或病毒血症。
- IL-1β信号在致关节炎甲病毒感染骨丢失中起关键作用。
核心结论
- 阿那白滞素治疗可能减轻RRV和CHIKV实验小鼠模型中的骨丢失。
- IL-1β信号在致关节炎甲病毒感染所致骨丢失中起关键作用,但阻断IL-1R未改善其他临床特征。
研究设计与样本
- 小鼠实验研究,每组n=5,感染RRV或CHIKV后给予阿那白滞素治疗。
- 测量体重增长和疾病严重程度,测定组织病毒滴度,评估关节组织学变化。
主要发现
- 阿那白滞素减轻RRV诱导的骨丢失(P < 0.001)和CHIKV诱导的骨丢失(P < 0.05)。
- 膝关节组织学分析显示阿那白滞素减少骨骺生长板变薄、骨骺骨体积丢失和胫骨破骨细胞生成。
- 药物性IL-1受体阻断未改善疾病评分、体重下降或病毒血症等其他临床特征。
关键数值与推荐
- 阿那白滞素减轻RRV诱导骨丢失的P < 0.001。
- 阿那白滞素减轻CHIKV诱导骨丢失的P < 0.05。
临床怎么用
- 阿那白滞素可能作为致关节炎甲病毒感染中骨丢失的潜在治疗选择,但需进一步临床研究验证。
- 临床使用阿那白滞素时需注意其可能不改善疾病评分、体重下降或病毒血症。
局限性
- 研究为小鼠实验模型,结果需在患者中进一步评估。
- 每组样本量较小(n=5)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Arthritogenic alphaviruses, such as Ross River virus (RRV) and chikungunya virus (CHIKV), particularly affect joints of the extremities and can lead to debilitating and potentially chronic polyarthritis/polyarthralgia. The innate immune response of the host plays a crucial role in inducing proinflammatory host factors, leading to tissue destruction and bone loss in the joints. This study was performed to assess how the inhibition of interleukin-1β (IL-1β) signaling using the clinical rheumatoid arthritis drug anakinra influences bone loss in mice with arthritogenic alphavirus infections. METHODS: Mice (n = 5 per group) were infected with RRV or CHIKV and then treated with anakinra. Weight gain and disease severity were measured, tissue viral titers were determined, and histologic changes in joint tissues were assessed. RESULTS: Anakinra therapy reduced RRV- and CHIKV-induced bone loss in this murine model (P < 0.001 and P < 0.05, respectively). Histologic analysis of the knee joint showed that treatment with anakinra decreased epiphyseal growth plate thinning, loss of epiphyseal bone volume, and osteoclastogenesis in the tibia. Importantly, pharmacologic IL-1 receptor (IL-1R) blockade did not improve other clinical features, including disease score, weight loss, or viremia. CONCLUSION: The present findings suggest that anakinra therapy may reduce bone loss in experimental murine models of RRV and CHIKV. Further investigations are needed to assess the potential therapeutic benefits of anakinra in patients with arthritogenic alphavirus disease.
引用
- Wolf S, Taylor A, Zaid A, et al. Inhibition of Interleukin-1β Signaling by Anakinra Demonstrates a Critical Role of Bone Loss in Experimental Arthritogenic Alphavirus Infections. Arthritis Rheumatol. 2019. PMID: 30747500. doi:10.1002/art.40856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。